Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Exam 2 Keystone > L19 - Obstructive Lung Diseases (COPD and Asthma) > Flashcards

L19 - Obstructive Lung Diseases (COPD and Asthma) Flashcards

1
Q

Prevelance of COPD now and in 2020

Ranking of COPD in terms of cause of death now and in 2020

A

World Health Organization predicts that by 2020 COPD will rise from its current ranking as the 12th most prevalent disease worldwide to the 5th; and from the 6th most common cause of death to the 3rd

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

COPD mortality is highest where worldwide?

Why?

A

In developing countries and asia

• Not only do to smoking, but also biomass fuels (indoor airpollution - common to indoor cooking)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Which is false regarding asthma effects in US society
A. 1 patients die of asthma every day
A. 39.5 million Americans have been diagnosed with asthma in their lifetime.
A. 13.2 million Americans had an asthma attack in 2011.
A. Economic cost from 2002 to 07 was $56.0 Billion dollars

A

A. 10

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Demographics of asthma

A

more common in women and in blacks. About equal prevalence in kids and adults
Overall prevalence is rising

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q 
COPD or Asthma?
	• Increasing prevalence 
	• Affects only adults
	• Increase mortality 
	• High Health Care Cost
A

COPD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q 
COPD or Asthma?
	• Increasing prevalence 
	• Affects both children and adults
	•  Decrease mortality
	• High Health Care Cost
A

Asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe fatal asthma

A
  • People who die from asthma have abnormal lungs with mucus plugs (corks in the airway) - prevent air from getting into the lung
  • Inhaled steroids prevent development of inflammation, which prevents development of mucus plugs
  • The mucus plugs cause mortality in asthma

General asthma (not fatal) have normal looking lungs

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

• Clinical diagnosis defined by the presence of chronic productive cough for three months in each of two successive years in a patient in whom other causes of chronic cough have been excluded

A

• Chronic bronchitis:

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

• Emphysema:

A

Is a pathological term describing the abnormal permanent enlargement of airspaces distal to the terminal bronchioles, accompanied by destruction of their walls without “obvious fibrosis”.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q 
Which is false about the pathologic features of asthmatic airways?
A. goblet cell hypoplasia
B. increased blood vessel numbers
C. Smooth muscle hyperplasia
D. Subepithelial fibrosis
E. mucus gland hypertrophy
F. reduced airway lumen area
A

A. Hyperplasia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Why is bronchial Wall Thickness important

A

• The degree of smooth muscle shortening required to produce airway closure is less in asthma patients than non-asthma patients (p

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q 
Which of the following does not increase to cause emphysema?
A. neutrophil elastase
B. alpha1-antitrypsin
C. Cathepsins
D. Matrix metalloproteinases (1,2,9,12)
A

B. This decreases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Which of the following does not decrease to cause emphysema?
A. Secretory leukoprotease inhibitor
B. elafin
C. Proteinase 3
D. Tissue inhibitors of matrix metalloproteinases

A

C. decreases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Describe the pathway of inflammatory mediators in asthma

A

Airway cell –> mediator –> physiological response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the diagnosis?
considered in current or former smokers (or in never smokers with other risk factors (noxious gases, ambient pollution and chronic respiratory infections)) who present with cough, sputum production, or dyspnea, with spirometric evidence of irreversible airflow obstruction

A

COPD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What is the diagnosis?
heterogeneous disease, usually characterized by chronic airway inflammation. It is defined by the history of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough that vary over time and in intensity, together with variable expiratory airflow limitation.

A

Asthma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Which is not a consequence of acute inflammation in asthma?
A. Altered airway physiology (inc airway hyperresponsiveness, inc airflow obstruction)
B. Acute inflammation
C. Resolution

A

B. Chronic inflammation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Does airway remodeling occur in mild asthma?

A

YES

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

COPD or Asthma?
A. sensitizing agent
B. airway inflammation with CD4 (+) T lymphocytes; eosinophils
C. reversible airflow limitation
D. younger, less likely to be smokers, intermittently symptomatic

A

ASTHMA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

COPD or Asthma?
A. noxious agent
B. airway inflammation (CD8+ T lymphocytes, macrophages/neutrophils)
C. airflow limitation irreversible
D. older, smokers, persistent, dyspnea, less responsive to inhalers

A

COPD

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What is the spirometry value of COPD patients?

A

FEV1/FVC ration

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

T/F Both spirometric evidence of airflow obstruction and clinical symptoms are necessary for the diagnosis of COPD

A

T

23
Q

WHich is false regarding GOLD COPD definition?
A• COPD is a preventable and treatable disease with some significant extrapulmonary effects that may contribute to the severity in individual patients
B• Its pulmonary component is characterized by airflow limitation that is fully reversible
C• Exacerbations and comorbidities contribute to the severity of the disease

A

B. is NOT fully reversible

24
Q

Which is not a systemic effect of COPD?
A• Cachexia,
B• Osteoporosis,
C• Hypercapnia-induced peripheral edema,
D• Neuro-psychiatric disorders, such as oxygen-related cognitive impairment and depression,
E• Excessive polycytemia
F• Weight loss
G• Venous thromboembolic disease (VTE)
H• Pulmonary Hypertension
I• Hormonal abnormalities (insulin, growth hormone, testosterone, and glucocorticoids)
J• Atherosclerosis

A

F• Sleep disorders are actually a systemic effect, not weight loss

25
Q

These symptoms are found with COPD or asthma?

  • Coughing (especially at night) - circadian rhythm of lungs (airways at night get smaller)
  • Wheezing
  • Chest tightness
  • Shortness of breath
A

Asthma

26
Q

What are some triggers of asthma?

A
  • Night-time: gastroesophageal reflux?
    • During/after exercise: exercise-induced asthma?
    • Seasonal: allergic asthma?
    • Coughing after laughing or crying?
    • Exposure to triggers at home, school, work?
27
Q

What are key findings in asthma physical exam?

A

• Chest
• Physical examination of the chest may be normal.
• Wheeezing or prolonged expiration during forced expiration.
○ (Wheezing and prolongation of expiratory phase does not correlate with the degree of airway obstruction measured by spirometry)
• Hyperinflation of the lungs
○ e.g. hyperresonance, diminished breath sounds
• Use of accessory muscles of respiration

28
Q

What are non-pulmonary signs of asthma on physical exam?

A
  • Non-Pulmonary (asthma)
    • Skin Signs: Atopic Dermatitis
    • Nasal Signs: Mucosal swelling, Polyps, Increased secretions
29
Q 
COPD or asthma?
Pulmonary function test 
- Spirometry: obstructive
- Lung volume: air trapping/hyperinflation
- DLCO: reduced
A

COPD

  • DLCO = diffusion capacity
    • Will be normal or increased bc doesn’t affect lung parenchyma (due to more blood flow)
    • In COPD it will be reduced
30
Q 
COPD or asthma?
Pulmonary function test
- spirometry: obstructive or normal
- lung volume: normal to air trapping and/or hyperinflation
- DLCO: normal or increased
A

Asthma

  • DLCO = diffusion capacity
    • Will be normal or increased bc doesn’t affect lung parenchyma (due to more blood flow)
    • In COPD it will be reduced
31
Q

What is this test?
• Measure FEV1 at each dose.
• When FEV1 drops to 20% - you stop
• If this happens at 5th does or lower = asthma
• If test is neg (never drop) - the person is very unlikely to have asthma
• This is a very sensitive test.

A

Methacholine challenge test to diagnose asthma

32
Q

What percent of peak flow variation is diagnostic of asthma?

A
  • If variation is beyond 20% = reactive airway disease (asthma)
  • Useful for occupational asthma - check peak flows at work and when off work
33
Q

Which is false regarding the natural history of COPD?
A. Smokers increase the rate at which they lose lung function over time
B. If you quit smoking, you can regain (increase) lung function
C. Never smokers typically have higher lung function than smokers over time

A

B. you can NOT, but the rate of loss will be that of as if you did not smoke after quitting

34
Q

What are the 3 stages in the natural history of asthma?

A
  1. acute response (bronchoconstriction, mediator release, edema, secretions, cough)
  2. Chronic inflammation (cell recruitment, epithelial damage, early structural changes)
  3. Airway remodeling (cell proliferation, increased ECM)
35
Q

List some genetic and environmental exposure risk factors that increase risk for COPD.

Do they influence lung growth in childhood?

A

Genetic: MMP12 SNP AA
Environmental: Smoking

Host characteristics (such as genetic makeup) and environmental exposures (such as smoking) influence lung growth in childhood and adolescence and determine the rate of decline in lung function in adulthood
	• Decline dependent of lung function you were able to reach when you were young.
36
Q

T/F COPD can overlap with other syndromes such as chronic bronchitis, emphysema, and asthma

A

True - there are various subsets of COPD

37
Q

T/F Pulmonary function tests are sufficient to diagnose emphysema

A

False - it is possible to have low FEV1 (which seems like emphysema) but now emphysema. Or normal FEV1, but imaging shows emphysema

Imaging (CT) and PFT are key

38
Q

COPD or asthma?

  • to stop the natural history you can:
    1. stop smoking
    2. tx asthma during childhood
A

COPD

39
Q

COPD or asthma?

  • to stop the natural history you can:
    1. avoid triggers
    2. use inhaled steroids (if in persistant stage)
A

asthma

40
Q

COPD severity classification by GOLD criteria is based on these 3 components

A
  1. airflow obstruction
  2. risk of exacerbations
  3. symptoms (mMRC or CAT score)
41
Q

Asthma classification is by…

A

Day and night symptoms

42
Q

Describe an acute COPD exacerbation

A

Feels like a heart attack

43
Q

COPD therapy is based on …

A
  1. GOLD classification
  2. PFT
  3. exacerbations
44
Q

Which is false regarding the therapeutic management of COPD?
A. Reduce exacerbations
B. Disease control
C. LABA alone can be used
D. ICS are only used in combination with LABA
E. Smoking cessation is key in the treatment of COPD (prevent progression of disease)

A

C. LAMA & LABA alone can be used

45
Q

Which is false regarding the therapeutic management of asthma?
A. Reduce exacerbation
B. Disease control
C. LABA alone is contraindicated
D. Limited data on LAMA use in asthma
E. ICS is not used in asthma therapy

A

E. • ICS are the cornerstone of asthma therapy

46
Q

Define:

  1. SAMA
  2. SBA
  3. LAMA
  4. LABA
  5. ICS
A
  • SAMA = Short acting muscarinic agent
  • SABA = Short acting beta against
  • LABA = Long activating broncodilator
  • LAMA = long acting muscarinic agent
  • ICS = inhaled corticosteroids
47
Q

What kind of treatment ALONE is a contraindicated in asthma?

A

LABA

48
Q

3 nonpharm therapies in COPD

A
  1. Oxygen therapy for patients with oxygen saturation ≤ 88% or ≤ 89% with evidence of cor pulmonale
  2. Vaccination (Influenza and Pneumonia)
  3. Pulmonary Rehabilitation
49
Q
  • PDE-4 inhibitor (phosphodiesterase inhibitor)

* Indicated in patients with frequent exacerbations, chronic bronchitis and FEV1

A

Roflumilast

For COPD exacerbations

50
Q
  • Unclear mechanism of action: Immunomodulation, antibiotics, change of airway microbiome
  • Given at 250 mg daily
  • Can interact with other drugs
  • QT prolongation on EKG
  • Potential hearing impairment
A

Azithromycin

For COPD exacerbations

51
Q

Which is not a new therapy in COPD treatment?
A. Targeting of different cytokines by using monoclonal antibodies (anti IL-13, IL-5, IL-8, IL-5 receptor, CCL-2)
B. Targeting different signal transduction pathways (anti p38, MAPK, NF-KB)
C. Classifying patients based on cell count differential (neutrophils vs eosinophils) and targeting therapies against these cells

A

All are new therapies

52
Q

• Binds free circulating IgE

Decreases symptoms and exacerbations

A

Omalizumab

Treatment of asthma

53
Q

• Inhibits IL-5, results in decrease eosinophilia.
• Increase quality of life, decrease exacerbations, decrease need for prednisone
Administered IV or subq can reduce exacerbations

A

Mepolizumab

Treatment of asthma

Exam 2 Keystone (13 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions